Boehringer Ingelheim (canada) Ltd.

Boehringer Ingelheim International Gmbh

Gilead Sciences, Inc.

Bio-mega/boehringer Ingelheim Research Inc.

Boehringer Ingelheim Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Teddy Halmos

Murray D Bailey

Montse Llinas-Brunet

Nathalie Goudreau

Elise Ghiro

Jean Rancourt

Youla S Tsantrizos

Marc-Andre Poupart

Anne-Marie Faucher

Dale R Cameron

Dominik M Wernic

Bruno Simoneau

Punit R Bhardwaj

Pasquale Forgione

Lee Fader

Marc-André Poupart

Stephen Kawai

Sylvie Goulet

Serge R Landry

Rebekah J Carson

Paul C Anderson

Sebastien Morin

Francois Bilodeau

Vida J Gorys

Grace L Jung

Josee Bordeleau

Mathieu Parisien

Rene Coulombe

Steven LaPlante

Marc-Andr E Poupart

Christiane Yoakim

Martin Duplessis

Clint A James

Claudio F Sturino

Paul John Edwards

Patrick Deroy

Eric Malenfant

Jean-Eric Lacoste

Louis Morency

Martin Tremblay

Joannie Minville

Dale Cameron

Marc-Andr&eacute; Poupart

Ellse Ghiro

François Bilodeau

Punit K Bhardwaj

Steven Laplantea

Claudio Sturino

Paul J Edwards

René Coulombe

Sébastien Morin

Compounds of formula I: wherein R, Rand Rare defined herein, are useful as inhibitors of HIV replication.

Inhibitors of human immunodeficiency virus replication

Compounds of formula I: wherein c, R, R, R, R, R, Rand Rare defined herein, are useful as inhibitors of HIV replication. 

Compounds of formula (I): wherein R, R, A, A, A, A, X and Y are as defined herein, are useful as inhibitors of HIV replication.

Inhibitors of HIV replication

Compounds of formula (I): wherein B, X, R, L, L, L, R, Rand Rare defined herein. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.

Hepatitis C inhibitor compounds

Racemates, diastereoisomers and optical isomers of a compound of formula (I):wherein

Hepatitis C inhibitor tri-peptides

Compounds of formula (I):  wherein R, R, R, R, n and m are as defined herein. The compounds are useful as inhibitors of HCV NS3 protease.

Hepatitis C inhibitor dipeptide analogs

Compounds of formula (I): wherein R, R, X, R, D, and the dotted line b are as defined herein; or a pharmaceutically acceptable salt or ester thereof, are useful as inhibitors of the HCV NS3 protease.

Macrocyclic peptides active against the hepatitis C virus

Racemates, diastereolsomers and optical isomers of a compound of formula (I):wherein B is H, a Cor Caryl, Caralkyl; Het or (lower alkyl)-Het, all of which optionally substituted with Calkyl; Calkoxy; Calkanoyl; hydroxy; hydroxyalkyl; halo; haloalkyl; nitro; cyano; cyanoalkyl; amino optionally substituted with Calkyl; amido; or (lower alkyl)amide; or

The invention relates to compounds of formula (I) wherein R', R, R, R, R, R, Y, n and m are as defined herein. The compounds are useful for the treatment and prevention of hepatitis C viral infections in mammals by inhibiting HCV NS3 protease. The invention further relates to azalactone compounds of the formula (III) which can be reacted with an amide anion to produce the compounds of formula (I). 

Hepatitis C inhibitor peptide analogs

Compounds of formula (I): wherein R, R, R, R, R, Y, n and m are as defined herein. The compounds are useful as inhibitors of HCV NS3 protease.

Compounds of formula I: wherein D, R, R, L, L, L, Rand Rare defined herein; or a pharmaceutically acceptable salt thereof, useful as inhibitors of the HCV NS3 protease.

Growing community of inventors

Laval, Canada

Teddy Halmos